Table 1 List of KIs included in the screening, their respective molecular targets and p-value of average length of neurite-like process per cell.
From: PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38MAPK signalling
Kinase inhibitor | Target | p-value (average length of branching) | Kinase inhibitor | Target | p-value (average length of branching) |
|---|---|---|---|---|---|
GDC-0068 | Akt | NS | BMS-265246 | CDK1/2 | ≤0.01 |
Phenformin HCl | AMPK | NS | CHIR-124 | Chk1 | ≤0.01 |
LY294002 | PI3Kα/δ/β | NS | 10058-F4 | c-Myc | NS |
LY2835219 | CDK4/6 | ≤0.001 | HMN-214 | PLK1 | ≤0.01 |
IM-12 | GSK-3 | NS | GSK461364 | PLK1 | NS |
Ridaforolimus (MK-8669) | mTOR | ≤0.05 | NSC 23766 | RAC | NS |
OSU-03012 (AR-12) | PDK-1 | NS | Nilotinib (AMN-107) | BCR-ABL | NS |
BX-912 | PDK-1 | NS | CNX-774 | BTK | ≤0.05 |
ZSTK474 | Class I PI3Ks | NS | TAE226 (NVP-TAE226) | FAK | ≤0.05 |
BGT226 (NVP-BGT226) | Class I PI3Ks, mTOR | NS | SSR128129E | FGFR1 | NS |
Pelitinib (EKB-569) | EGFR | ≤0.001 | KX2-391 | SRC | ≤0.01 |
OSI-420 | EGFR | NS | JNK-IN-8 | JNK1/2/4 | NS |
AZD9291 | EGFR | ≤0.05 | PD184352 (CI-1040) | MEK1/2 | ≤0.05 |
Chrysophanic Acid | mTOR, EGFR | NS | Trametinib (GSK1120212) | MEK1/2 | ≤0.05 |
CP-673451 | PDGFRα/β | ≤0.001 | LY2228820 | p38 MAPK | NS |
Masitinib (AB1010) | PDGFR, c-Kit | NS | ZM 336372 | C-RAF | NS |
Tie2 kinase inhibitor | Tie-2 | NS | TAK-632 | RAF | NS |
Vandetanib (ZD6474) | VEGFR2 | ≤0.05 | CEP-33779 | JAK2 | NS |
Semaxanib (SU5416) | VEGFR (FLK1/KDR) | NS | Pacritinib (SB1518) | JAK2, FLT3 | ≤0.001 |
Sunitinib Malate | VEGFR, PDGFRβ, c-Kit | NS | SMI-4a | PIM1 | NS |
NU7441 (KU-57788) | DNA-PK, PI3K | ≤0.01 | GNE-7915 | LRRK2 | NS |
MLN8054 | Aurora A | NS | PFK15 | PFKFB3 | NS |
Aurora A Inhibitor I | Aurora A | ≤0.05 | KN-62 | CaMKII | NS |
BS-181 HCl | CDK7 | NS |
